• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


IBM Resignations

























I am willing to bet a large portion of the IBM team has feelers out. This year has been one huge disaster after another. And no one making the crazy 300% growth quota. They track us on Motus like primary care reps. And we sell one product in a declining market, one with bad contracting, and the third facing generic intrusion. I bet we lose at least 2 more by Q4.